

Giuseppe Palmieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/265162/publications.pdf>

Version: 2024-02-01

162
papers

15,856
citations

87723

38
h-index

17546

121
g-index

175
all docs

175
docs citations

175
times ranked

21353
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 612.	1.8	79
2	Fluorescence-Guided Surgery for High-Grade Gliomas: State of the Art and New Perspectives. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110216.	0.8	22
3	Posterior arch reconstruction in cervical surgery to restore the global biomechanics of the Atlas: a technical note. <i>British Journal of Neurosurgery</i> , 2021, , 1-4.	0.4	0
4	Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. <i>Current Medicinal Chemistry</i> , 2021, 28, 2234-2247.	1.2	7
5	NGS-Based Analysis of Atypical Deep Penetrating Nevi. <i>Cancers</i> , 2021, 13, 3066.	1.7	10
6	The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7160.	1.8	4
7	The Relevant Role of Navigated Tractography in Speech Eloquent Area Glioma Surgery: Single Center Experience. <i>Brain Sciences</i> , 2021, 11, 1436.	1.1	4
8	Separation surgery for metastatic epidural spinal cord compression: A qualitative review. <i>Journal of Bone Oncology</i> , 2020, 25, 100320.	1.0	43
9	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2430.	1.0	10
10	Primary Melanoma of the Lung: A Systematic Review. <i>Medicina (Lithuania)</i> , 2020, 56, 576.	0.8	12
11	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiReA® Panel. <i>Frontiers in Oncology</i> , 2020, 10, 236.	1.3	11
12	Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren. <i>Medicine (United States)</i> , 2020, 99, e18078.	0.4	2
13	Genetic Instability Markers in Cancer. <i>Methods in Molecular Biology</i> , 2020, 2055, 133-154.	0.4	2
14	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	1.1	24
15	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	1.8	27
16	Developmental Gene Markers in Tumor Pathogenesis and Progression. <i>Disease Markers</i> , 2019, 2019, 1-2.	0.6	0
17	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 756-767.	1.2	37
18	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 209.	0.8	29

#	ARTICLE	IF	CITATIONS
19	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
20	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. Journal of Translational Medicine, 2019, 17, 289.	1.8	24
21	Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. Metallomics, 2019, 11, 1687-1699.	1.0	41
22	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. Journal of Clinical Medicine, 2019, 8, 1577.	1.0	9
23	Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective. Nutrition and Metabolism, 2019, 16, 33.	1.3	13
24	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
25	Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. Diagnostics, 2019, 9, 42.	1.3	0
26	Prognostic impact of regression in patients with primary cutaneous melanoma >1mm in thickness. Journal of the American Academy of Dermatology, 2019, 80, 99-105.e5.	0.6	19
27	Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature. Clinical Respiratory Journal, 2018, 12, 848-856.	0.6	6
28	Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. Current Oncology Reports, 2018, 20, 86.	1.8	61
29	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	3.4	31
30	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. International Journal of Oncology, 2018, 53, 1149-1159.	1.4	12
31	Pathology and Genetics of Melanoma. , 2018, , .		0
32	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. International Journal of Molecular Sciences, 2018, 19, 47.	1.8	17
33	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
34	Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations. European Journal of Dermatology, 2018, 28, 149-156.	0.3	5
35	Genetic alterations in main candidate genes during melanoma progression. Oncotarget, 2018, 9, 8531-8541.	0.8	50
36	Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy. European Journal of Cancer Prevention, 2017, 26, 263-267.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 17.	1.8	40
38	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	1.8	85
39	Long non-coding RNA CASC2 in human cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 31-38.	2.0	54
40	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.	2.1	34
41	Antitumoral effect of vanadium compounds in malignant melanoma cell lines. <i>Journal of Inorganic Biochemistry</i> , 2017, 174, 14-24.	1.5	66
42	Vitamin D status and risk for malignant cutaneous melanoma: recent advances. <i>European Journal of Cancer Prevention</i> , 2017, 26, 532-541.	0.6	30
43	Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. <i>International Journal of Dermatology</i> , 2017, 56, 792-794.	0.5	4
44	A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. <i>Hepatology</i> , 2017, 66, 167-181.	3.6	119
45	Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017, 38, 2741-2751.	1.2	22
46	Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 575-581.	0.9	21
47	Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. <i>Retrovirology</i> , 2017, 14, 3.	0.9	9
48	The panitumumab with FOLFOX4 in metastatic gastric or gastroesophageal junction adenocarcinoma (mGA) - VEGA trial. Efficacy and safety outcomes of a phase II S.I.C.O.G. study. <i>Annals of Oncology</i> , 2017, 28, iii40.	0.6	1
49	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. <i>Journal of Translational Medicine</i> , 2017, 15, 227.	1.8	10
50	Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. <i>Oncotarget</i> , 2017, 8, 90638-90650.	0.8	17
51	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. <i>Oncotarget</i> , 2017, 8, 80393-80404.	0.8	16
52	What is changing in the adjuvant treatment of melanoma?. <i>Oncotarget</i> , 2017, 8, 110735-110736.	0.8	2
53	Perivascular Epithelioid Cell Tumors (PEComas) of the Orbit. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 7-8.	0.4	5
54	Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6. <i>BMC Cancer</i> , 2016, 16, 317.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. <i>Oncology Letters</i> , 2016, 12, 1415-1421.	0.8	3
56	Breast Nodular Fasciitis: A Comprehensive Review. <i>Breast Care</i> , 2016, 11, 270-274.	0.8	32
57	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.	0.3	13
58	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. <i>Journal of Translational Medicine</i> , 2016, 14, 292.	1.8	43
59	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1914-1917.	0.3	16
60	Parental Use and Educational Campaigns on Sunbed Use Among Teenagers and Adolescents. <i>Medicine (United States)</i> , 2016, 95, e3034.	0.4	14
61	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.	0.6	32
62	Antitumor Activity of BRAF Inhibitor and IFN γ Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv435.	3.0	35
63	<i>MC1R</i> variants increased the risk of sporadic cutaneous melanoma in darker pigmented Caucasians: A pooled analysis from the M-Skip project. <i>International Journal of Cancer</i> , 2015, 136, 618-631.	2.3	92
64	Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 747-751.	1.5	2
65	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. <i>Molecular Medicine Reports</i> , 2015, 12, 187-191.	1.1	14
66	A Study of Inflammatory/Necrosis Biomarkers in the Fracture of the Femur Treated with Proximal Femoral Nail Antirodation. <i>Mediators of Inflammation</i> , 2015, 2015, 1-5.	1.4	9
67	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183.	1.3	80
68	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	2.1	28
69	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>Journal of Translational Medicine</i> , 2015, 13, 37.	1.8	15
70	The immune-related role of BRAF in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, K19.	1.8	0
71	Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. <i>BMC Cancer</i> , 2015, 15, 383.	1.1	12
72	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	2.1	318

#	ARTICLE	IF	CITATIONS
73	Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. <i>Oncology Letters</i> , 2014, 7, 948-952.	0.8	16
74	ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. <i>Journal of Translational Medicine</i> , 2014, 12, 272.	1.8	8
75	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. <i>Metabolomics</i> , 2014, 10, 1026-1035.	1.4	7
76	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 216.	1.8	43
77	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	2.0	230
78	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	1.8	24
79	KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. <i>Oncology Letters</i> , 2014, 8, 1422-1426.	0.8	21
80	Molecular Pathology of Melanocytic Skin Cancer. , 2014, , 59-74.		0
81	Do BRAF inhibitors select for populations with different disease progression kinetics?. <i>Journal of Translational Medicine</i> , 2013, 11, 61.	1.8	25
82	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- α in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	1.8	21
83	Molecular analysis of appendiceal mucinous cystadenoma and rectal adenocarcinoma in a patient with urothelial carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 170.	0.4	5
84	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. <i>BMC Cancer</i> , 2013, 13, 17.	1.1	38
85	Molecular changes induced by the curcumin analogue D6 in human melanoma cells. <i>Molecular Cancer</i> , 2013, 12, 37.	7.9	21
86	Lung cancer epidemiology in North Sardinia, Italy. <i>Multidisciplinary Respiratory Medicine</i> , 2013, 8, 45.	0.6	29
87	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	1.8	31
88	Unexpected Distribution of β -catenin, cKIT and BRAF Mutations among Southern Italian Patients with Sinonasal Melanoma. <i>Dermatology</i> , 2013, 226, 279-284.	0.9	36
89	Epidemiology of Thyroid Cancer in an Area of Epidemic Thyroid Goiter. <i>Journal of Cancer Epidemiology</i> , 2013, 2013, 1-4.	0.5	11
90	Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1685-1687.	0.3	8

#	ARTICLE	IF	CITATIONS
91	Surgical Management of Suspicious Melanocytic Lesions in Italy. <i>Dermatology</i> , 2013, 226, 18-21.	0.9	1
92	Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy. <i>Dermatology</i> , 2013, 226, 7-12.	0.9	5
93	Impact of Mole Mapping in the Italian Health System. <i>Dermatology</i> , 2013, 226, 13-17.	0.9	2
94	Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization. <i>Case Reports in Dermatology</i> , 2013, 5, 192-197.	0.3	7
95	Estimates of cancer burden in Sardinia. <i>Tumori</i> , 2013, 99, 408-415.	0.6	7
96	Diagnostic Services for Melanoma in Italy. <i>Dermatology</i> , 2013, 226, 3-6.	0.9	2
97	Estimates of cancer burden in Sardinia. <i>Tumori</i> , 2013, 99, 408-15.	0.6	7
98	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	0.8	419
99	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
100	Reproductive aging-associated common genetic variants and the risk of breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R54.	2.2	17
101	NF- κ B as potential target in the treatment of melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 53.	1.8	118
102	Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. <i>Journal of Translational Medicine</i> , 2012, 10, 178.	1.8	31
103	NF- κ B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. <i>Journal of Translational Medicine</i> , 2012, 10, 252.	1.8	32
104	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	1.8	563
105	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. <i>BMC Medical Research Methodology</i> , 2012, 12, 116.	1.4	12
106	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	0.4	24
107	Proteomic Profiling of Human Melanoma Metastatic Cell Line Secretomes. <i>Journal of Proteome Research</i> , 2011, 10, 4703-4714.	1.8	23
108	Melanoma: From Research to Treatment. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-2.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. <i>Oncology Reports</i> , 2011, 25, 899-904.	1.2	1
110	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011, 25, 1495-502.	1.2	19
111	Monitoring liver alterations during hepatic tumorigenesis by NMR profiling and pattern recognition. <i>Metabolomics</i> , 2010, 6, 405-416.	1.4	11
112	Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. <i>BMC Cancer</i> , 2010, 10, 458.	1.1	11
113	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. <i>Clinical Immunology</i> , 2010, 134, 237-250.	1.4	131
114	The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatology</i> , 2010, 10, 5.	2.1	13
115	Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. <i>Molecular Cancer</i> , 2010, 9, 137.	7.9	44
116	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon- γ 2b treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 76.	1.8	39
117	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. <i>Cell Cycle</i> , 2009, 8, 1228-1237.	1.3	11
118	A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population. <i>BMC Cancer</i> , 2009, 9, 245.	1.1	18
119	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009, 9, 352.	1.1	42
120	Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. <i>BMC Cancer</i> , 2009, 9, 62.	1.1	16
121	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. <i>BMC Dermatology</i> , 2009, 9, 7.	2.1	8
122	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009, 274, 331-336.	3.2	30
123	Main roads to melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 86.	1.8	157
124	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. <i>Melanoma Research</i> , 2009, 19, 142-145.	0.6	20
125	Presence of Jaagsiekte sheep retrovirus in tissue sections from human bronchioloalveolar carcinoma depends on patients' geographical origin. <i>Human Pathology</i> , 2008, 39, 303-304.	1.1	16
126	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. <i>Journal of Clinical Oncology</i> , 2007, 25, e20-e21.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>European Journal of Cancer</i> , 2007, 43, 137-143.	1.3	28
128	Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. <i>Molecular Cancer</i> , 2007, 6, 8.	7.9	106
129	2,2â€²-Dihydroxy-3,3â€²-dimethoxy-5,5â€²-dimethyl-6,6â€²-dibromo-1,1â€²-biphenyl: preparation, resolution, structure and biological activity. <i>Tetrahedron: Asymmetry</i> , 2007, 18, 414-423.	1.8	4
130	Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. <i>BMC Cancer</i> , 2007, 7, 132.	1.1	15
131	Adjuvant treatment of malignant melanoma: Where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 45-52.	2.0	10
132	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> , 2006, 6, 266.	1.1	19
133	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005, 15, 235-244.	0.6	50
134	Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. <i>Cancer</i> , 2005, 104, 1172-1179.	2.0	24
135	Classic follicular dendritic reticulum cell tumor of the lymph node developing in a patient with a previous inflammatory pseudotumor-like proliferation. <i>Human Pathology</i> , 2005, 36, 207-211.	1.1	11
136	Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma. <i>European Journal of Cancer</i> , 2005, 41, 1058-1064.	1.3	4
137	Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells. <i>Cancer Research</i> , 2004, 64, 3037-3045.	0.4	233
138	BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 286-292.	0.8	55
139	Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. <i>Cancer Cell</i> , 2004, 5, 137-149.	7.7	132
140	Distribution and significance of 14-3-3Ïƒf, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. <i>Journal of Pathology</i> , 2004, 202, 274-285.	2.1	67
141	Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. <i>Human Mutation</i> , 2004, 23, 318-326.	1.1	86
142	High-resolution methylation analysis of the MLH1 promoter in sporadic endometrial and colorectal carcinomas. <i>Cancer</i> , 2003, 98, 1540-1546.	2.0	31
143	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	0.8	91
144	X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3311-3314.	3.3	121

#	ARTICLE	IF	CITATIONS
145	Mutation analysis of candidate genes in melanoma-prone families. <i>Melanoma Research</i> , 2003, 13, 571-579.	0.6	11
146	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003, 13, 167-170.	0.6	35
147	Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. <i>Cancer</i> , 2002, 94, 3157-3168.	2.0	39
148	Mutations of the BRAF gene in human cancer. <i>Nature</i> , 2002, 417, 949-954.	13.7	9,374
149	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Clinical Oncology</i> , 2001, 19, 1437-1443.	0.8	63
150	Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001, 11, 83-84.	0.6	1
151	Human <i>dbl</i> proto-oncogene in 85 kb of Xq26, and determination of the transcription initiation site. <i>Gene</i> , 2000, 253, 107-115.	1.0	3
152	Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. <i>Journal of Clinical Oncology</i> , 1999, 17, 304-304.	0.8	109
153	Association of polo-like kinase with α -, β - and γ -tubulins in a stable complex. <i>Biochemical Journal</i> , 1999, 339, 435.	1.7	27
154	Construction of a pilot human YAC library in a recombination-defective yeast strain. <i>Gene</i> , 1997, 188, 169-174.	1.0	6
155	Significance of Methotrexate Serum Level Achieved in Patients with Gastrointestinal Malignancies Treated with Sequential Methotrexate, &Folinic Acid and 5-Fluorouracil. <i>Oncology</i> , 1996, 53, 198-203.	0.9	5
156	Dose-Finding Study of 5-Deoxy-5-Fluorouridine in Combination with Fixed Doses of Cisplatin and &Folinic Acid for the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Oncology</i> , 1995, 52, 326-330.	0.9	1
157	YAC Contig Organization and CpG Island Analysis in Xq28. <i>Genomics</i> , 1994, 24, 149-158.	1.3	44
158	1.5-Mb YAC Contig in Xq28 Formatted with Sequence-Tagged Sites and Including a Region Unstable in the Clones. <i>Genomics</i> , 1993, 16, 586-592.	1.3	14
159	Actin-Binding Protein (ABP-280) Filamin Gene (FLN) Maps Telomeric to the Color Vision Locus (R/GCP) and Centromeric to G6PD in Xq28. <i>Genomics</i> , 1993, 17, 496-498.	1.3	36
160	An archipelago of CpG islands in Xq28: identification and fine mapping of 20 new CpG islands of the human X chromosome. <i>Human Molecular Genetics</i> , 1992, 1, 275-280.	1.4	26
161	The iduronate sulfatase gene: Isolation of a 1.2-Mb YAC contig spanning the entire gene and identification of heterogeneous deletions in patients with Hunter syndrome. <i>Genomics</i> , 1992, 12, 52-57.	1.3	43
162	Human glucose-6-phosphate dehydrogenase gene carried on a yeast artificial chromosome encodes active enzyme in monkey cells. <i>Genomics</i> , 1990, 7, 531-534.	1.3	38